HALO - Halozyme Therapeutics Non-GAAP EPS of $0.74 beats by $0.23 revenue of $208.98M beats by $17.81M

• Halozyme Therapeutics press release ( NASDAQ: HALO ): Q3 Non-GAAP EPS of $0.74 beats by $0.23 .
• Revenue of $208.98M (+80.4% Y/Y) beats by $17.81M .
• FY2022 Outlook : Total revenue of $655M to $685M vs. consensus of $661.35M; GAAP operating income of $240M to $265M; GAAP net income of $170M to $195M and non-GAAP net income of $295M to $320M; GAAP diluted earnings per share of $1.20 to $1.35 due to acquisition related costs in 2022; Non-GAAP diluted earnings per share are expected to be $2.10 to $2.25 vs. consensus of $2.04.

For further details see: